INTRODUCTION
============

The accurate duplication of the genome is crucial for the prolonged health of eukaryotic organisms. Inaccurate DNA replication and/or replication of any portion of the genome more than once can result in genomic instability, which is a consistently observed hallmark of cancer cells ([@B60]; [@B61]). It is crucial, therefore, to understand the entire process of DNA replication. The initiation of DNA replication requires the coordinated recruitment of several proteins. Prereplicative complexes ([@B14]), including the core helicase Mcm2--7 ([@B4]), form at origins of replication, are converted to pre-initiation complexes ([@B70]), and DNA is subsequently unwound (reviewed in [@B2]). Once the DNA is unwound, the accuracy of DNA replication depends in large part upon DNA polymerases (pol)-α, -δ, and -ε, all of which coordinate to synthesize the nascent copy of DNA during replication in eukaryotes ([@B7]). Highlighting the importance of accurate DNA replication, 43% of mice homozygous for a proofreading-deficient allele of pol-δ develop cancer, primarily lymphoma, but also squamous-cell carcinoma ([@B21]). Interestingly, pol-α, the only enzyme that can synthesize DNA de novo, naturally lacks proofreading activity ([@B40]). Unlike pol-δ, pol-α is foremost a replicative --- and not a repair --- polymerase ([@B67]; [@B64]). The lack of proofreading activity likely reflects one mechanism by which nature enforces evolution. However, this raises the question of how humans use a potentially mutagenic polymerase responsible for the initiation of more than 30 million Okazaki fragments without regularly developing cancer. Fortunately, pol-α incorporates only 12--20 nucleotides before turning over bulk DNA synthesis to either pol-δ (lagging strand) or pol-ε (leading strand), both of which are more processive and contain proofreading activity ([@B45]; [@B40]; [@B62]; [@B19]; [@B49]; [@B46]).

The fact that pol-α is limited to synthesizing only 12--20 nucleotides of DNA implies a very tight regulation of this enzyme. Our laboratory and others have shown previously that minichromosome maintenance (Mcm) 10 interacts with the catalytic subunit of pol-α in budding and fission yeast and higher eukaryotes ([@B16]; [@B50], [@B51]; [@B8]; [@B68]; [@B52]). Mcm10 is an essential DNA replication factor that is conserved from yeast to humans ([@B36]; [@B1]; [@B27]; [@B28]). It associates with replication origins before replication initiates and is required for the stable association of pol-α with chromatin ([@B50]). In addition to interacting with the catalytic subunit of pol-α, Mcm10 also binds to proliferating cell nuclear antigen (PCNA), the processivity clamp for both DNA pol-δ and -ε. The interaction between Mcm10 and PCNA is essential in budding yeast and depends on diubiquitination of Mcm10 ([@B12]). At the same time, this modification appears to inhibit the interaction between Mcm10 and pol-α ([@B12]). These data suggest that Mcm10 plays an integral role in the switch from pol-α to pol-δ and pol-ε. As mentioned above, Mcm10 does not only interact with Cdc17 it also regulates its stability ([@B50]), and this function is evolutionarily conserved ([@B8]). The catalytic subunit of pol-α is rapidly degraded after depletion of Mcm10 from yeast and human cells ([@B50]; [@B8]). However, the pathway responsible for this degradation is not known.

The ubiquitin-mediated degradation system is a major proteolytic pathway in cells. In this system, ubiquitin, an 8-kDa peptide, is transferred from an ubiquitin activating (E1) enzyme to an ubiquitin conjugating (E2) enzyme, then to an ubiquitin ligase (E3) and finally, to the target protein ([@B24]). This process is repeated several times to polyubiquitinate the protein and this serves as a signal for degradation by the proteasome, a large, multisubunit proteolytic machine ([@B59]). The fact that Cdc17 is rapidly degraded in the absence of Mcm10 suggests that it might be a target of proteasomal degradation.

Here, we first sought to elucidate the mechanism of Cdc17 degradation in the absence of Mcm10. We found that Cdc17 was degraded via the proteasome and we identified ubiquitin conjugating enzyme (Ubc) 4 and negative regulator of transcription (Not) 4 as the E2 and E3 enzymes required for the destabilization of Cdc17. Although we were unable to detect ubiquitin conjugates of Cdc17, protein turnover clearly depended on ubiquitination. Moreover, overexpression of Cdc17 resulted in slow growth of *ubc4*Δ mutants and revealed synthetic dosage lethality (SDL) with a *NOT4* deletion. Lastly, cooverexpression of Cdc17 and Mcm10 exhibited a similar slow growth phenotype and a significant increase in microsatellite-mediated DNA rearrangements. Our results suggest that Cdc17 levels are carefully regulated in the cell through Ubc4- and Not4-dependent destabilization counterbalanced by Mcm10-dependent stabilization. We propose that tipping this balance in favor of increasing Cdc17 and Mcm10 levels causes genomic instability.

MATERIALS AND METHODS
=====================

Strains and Plasmids
--------------------

Strains are isogenic derivatives of either W303-1a or S288C. All strains carrying gene deletions were constructed using a PCR-based gene disruption method ([@B6]). The genotypes of the yeast strains used in this study are listed in [Table 1](#T1){ref-type="table"}. All plasmids were constructed using standard molecular cloning techniques. pRS316*-NOT4* was constructed by cloning the entire *NOT4* coding sequence as well as 497 base pairs of promoter sequence into pRS316. Site-directed mutagenesis was used to generate pRS316-*not4-L35A* from pRS316*-NOT4*. The 3HA tag was added by PCR. Strains ABy661 and ABy1051 were constructed by transforming plasmid YEp105, which harbors a synthetic Myc-tagged ubiquitin gene ([@B15]), and YEp105-G75,76A ([@B13]) into ABy527, respectively.

###### 

List of yeast strains used in this study

  Strain name                                                                                    Relevant genotype                                                                                      Source
  ---------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ -----------------------------
  Strains derived from W303-1a (*MATa ura3-1 ade 2-1 his3-11,-15 leu2-3,-112 can1-100 trp1-1*)                                                                                                          
      ABy013                                                                                     *mcm10-1, CDC17::3HA-TRP1*                                                                             [@B50]
      ABy342                                                                                     *mcm10-1, ubc4::LEU2, CDC17::3HA-TRP1*                                                                 This study
      ABy455                                                                                     *mcm10-1, UBC4::NES-3HA-URA3, CDC17::3HA-TRP1*                                                         This study
      ABy529                                                                                     *mcm10-1, not4::LEU2, CDC17::3HA-TRP1*                                                                 This study
      ABy363                                                                                     *mcm10-1, ubc5::LEU2, CDC17::3HA-TRP1*                                                                 This study
      ABy359                                                                                     *mcm10-1, rad6::LEU2, CDC17::3HA-TRP1*                                                                 This study
      ABy360                                                                                     *mcm10-1, ubc13::LEU2, CDC17::3HA-TRP1*                                                                This study
      ABy361                                                                                     *mcm10-1, mms2::LEU2*, *CDC17::3HA-TRP1*                                                               This study
      ABy781                                                                                     *mcm10-1, CDC17::3HA-TRP1*, pRS316                                                                     This study
      ABy762                                                                                     *mcm10-1, not4::LEU2, CDC17::3HA-TRP1*, pRS316                                                         This study
      ABy738                                                                                     *mcm10-1, not4::LEU2, CDC17::3HA-TRP1*, pRS316-*NOT4*                                                  This study
      ABy739                                                                                     *mcm10-1, not4::LEU2, CDC17::3HA-TRP1*, pRS316-*not4-L35A*                                             This study
      ABy596                                                                                     *mcm10-1, CDC17::3HA-TRP1, NOT4::3HA-URA3*                                                             This study
      ABy740                                                                                     *mcm10-1, not4::LEU2, CDC17::3HA-TRP1*, pRS316-*NOT4-3HA*                                              This study
      ABy741                                                                                     *mcm10-1, not4::LEU2, CDC17::3HA-TRP1*, pRS316-*not4-L35A-3HA*                                         This study
      ABy448                                                                                     *CDC17::3HA-TRP1*                                                                                      This study
      ABy607                                                                                     *ubc4::LEU2, CDC17::3HA-TRP1*                                                                          This study
      ABy597                                                                                     *not4::LEU2, CDC17::3HA-TRP1*                                                                          This study
      ABy662                                                                                     *UBC4::NES-3HA-URA3, CDC17::3HA-TRP1*                                                                  This study
      ABy764                                                                                     *ubc5::LEU2, CDC17::3HA-TRP1*                                                                          This study
      ABy605                                                                                     *mcm10-1, UBC4::GFP-HIS3*                                                                              This study
      ABy660                                                                                     *mcm10-1, UBC4::NES-GFP-HIS3*                                                                          This study
      ABy527                                                                                     *mcm10-1, pdr5::LEU2, rpn4::HIS3, CDC17::2HA-URA3*                                                     This study
      ABy661                                                                                     *mcm10-1, pdr5::LEU2, rpn4::HIS3, CDC17::2HA-URA3*, YEp105                                             This study
      ABy1051                                                                                    *mcm10-1, pdr5::LEU2, rpn4::HIS3, CDC17::2HA-URA3*, YEp105-G75,76A                                     This study
      ABy640                                                                                     pSH44, pRS423gal, pRS425gal                                                                            This study
      ABy641                                                                                     pSH44, pRS423gal, pRS425gal-*CDC17-2HA*                                                                This study
      ABy642                                                                                     pSH44, pRS423gal-*MCM10-3HA*, pRS425gal                                                                This study
      ABy643                                                                                     pSH44, pRS423gal-*MCM10-3HA*, pRS425gal-*CDC17-2HA*                                                    This study
      ABy695                                                                                     pRS423gal, pRS424gal, pRS425gal, pRS426gal                                                             This study
      ABy694                                                                                     pRS423gal, pRS424gal, pRS425gal, pRS426gal-*CDC17-2HA*                                                 This study
      ABy696                                                                                     pRS423gal-*MCM10-3HA*, pRS424gal, pRS425gal, pRS426gal                                                 This study
      ABy705                                                                                     pRS423gal-*MCM10-3HA*, pRS424gal, pRS425gal, pRS426gal-*CDC17-2HA*                                     This study
      ABy732                                                                                     pRS423gal-*MCM10-3HA*/*POL12-3HA*, pRS424gal-*PRI1-3HA*/*PRI2-3HA*, pRS425gal, pRS426gal-*CDC17-3HA*   This study
      ABy962                                                                                     pRS423gal                                                                                              This study
      ABy963                                                                                     pRS423gal-*CDC17-2HA*                                                                                  This study
      ABy964                                                                                     pRS423gal-*MCM10-3HA*                                                                                  This study
      ABy965                                                                                     *ubc4::LEU2*, pRS423gal                                                                                This study
      ABy966                                                                                     *ubc4::LEU2*, pRS423gal-*CDC17-2HA*                                                                    This study
      ABy967                                                                                     *ubc4::LEU2*, pRS423gal-*MCM10-3HA*                                                                    This study
      ABy968                                                                                     *ubc5::LEU2*, pRS423gal                                                                                this study
      ABy969                                                                                     *ubc5::LEU2*, pRS423gal-*CDC17-2HA*                                                                    This study
      ABy970                                                                                     *ubc5::LEU2*, pRS423gal-*MCM10-3HA*                                                                    This study
      ABy971                                                                                     *ubc4::LEU2, ubc5::TRP1*, pRS423gal                                                                    This study
      ABy972                                                                                     *ubc4::LEU2, ubc5::TRP1*, pRS423gal-*CDC17-2HA*                                                        This study
      ABy973                                                                                     *ubc4::LEU2, ubc5::TRP1*, pRS423gal-*MCM10-3HA*                                                        This study
      ABy974                                                                                     *not4::LEU2*, pRS423gal                                                                                This study
      ABy975                                                                                     *not4::LEU2*, pRS423gal-*CDC17-2HA*                                                                    This study
      ABy976                                                                                     *not4::LEU2*, pRS423gal-*MCM10-3HA*                                                                    This study
      ABy977                                                                                     pRS316-*TRP1*, pRS423gal, pRS425gal                                                                    This study
      ABy978                                                                                     pRS316-*TRP1*, pRS423gal, pRS425gal-*CDC17-2HA*                                                        This study
      ABy979                                                                                     pRS316-*TRP1*, pRS423gal-*MCM10-3HA*, pRS425gal                                                        This study
      ABy980                                                                                     pRS316-*TRP1*, pRS423gal-*MCM10-3HA*, pRS425gal-*CDC17-2HA*                                            This study
      ABy831                                                                                     *ubc4::LEU2*, *CDC17::3HA-TRP1*, pRS426gal-*CDC17-2HA*                                                 This study
      ABy837                                                                                     *not4::LEU2*, *CDC17::3HA-TRP1*, pRS426gal-*CDC17-2HA*                                                 This study
      ABy981                                                                                     *CDC17::3HA-TRP1*, pRS426gal-*CDC17-2HA*                                                               This study
  Strains derived from S288C (*MATa his*Δ*1 leu2*Δ*0 met15*Δ*0 ura3*Δ*0*)                                                                                                                               
      ABy150                                                                                     *MATa his*Δ*1 leu2*Δ*0 met15*Δ*0 ura3*Δ*0*                                                             Mortimer and Johnston, 1986
      ABy152                                                                                     *ubc4::KANMX*                                                                                          This study
      ABy575                                                                                     *not4::LEU2*                                                                                           This study
      ABy574                                                                                     *UBC4::NES-3HA-URA3*                                                                                   This study
      ABy577                                                                                     *ubc5::LEU2, UBC4::NES-3HA-URA3*                                                                       This study
      GAP510                                                                                     *ubc4::HIS3, ubc5::LEU2*                                                                               Trotter *et. al.*, 2001
      ABy258                                                                                     pRS426gal-*CDC17-2HA*                                                                                  This study
      ABy259                                                                                     *rad6::KANMX*, pRS426gal-*CDC17-2HA*                                                                   This study
      ABy260                                                                                     *ubc4::KANMX*, pRS426gal-*CDC17-2HA*                                                                   This study
      ABy261                                                                                     *ubc5::KANMX*, pRS426gal-*CDC17-2HA*                                                                   This study
      ABy262                                                                                     *ubc7::KANMX*, pRS426gal-*CDC17-2HA*                                                                   This study
      ABy263                                                                                     *ubc8::KANMX*, pRS426gal-*CDC17-2HA*                                                                   This study
      ABy264                                                                                     *ubc10::KANMX*, pRS426gal-*CDC17-2HA*                                                                  This study
      ABy265                                                                                     *ubc13::KANMX*, pRS426gal-*CDC17-2HA*                                                                  This study
      ABy266                                                                                     *mms2::KANMX*, pRS426gal-*CDC17-2HA*                                                                   This study
      ABy267                                                                                     *rtt101::KANMX*, pRS426gal-*CDC17-2HA*                                                                 This study
      ABy268                                                                                     *cul3::KANMX*, pRS426gal-*CDC17-2HA*                                                                   This study
      ABy563                                                                                     pRS426gal-*CDC17-2HA*                                                                                  This study
      ABy564                                                                                     pRS423gal-*MCM10-3HA*                                                                                  This study
      ABy565                                                                                     pRS423gal-*MCM10-3HA*, pRS426gal-*CDC17-2HA*                                                           This study

Protein Preparation and Western Blot Analysis
---------------------------------------------

Total protein extracts were prepared as described previously by trichloroacetic acid extraction ([@B51]). Proteins were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and probed by Western blot with anti-HA (16B12; Covance, Princeton, NJ) for HA-tagged proteins and anti--α-tubulin (B512; Covance). Alexa Fluor 680 (Invitrogen, Carlsbad, CA) secondary antibody was used to visualize proteins with Odyssey v3.0 software on an Odyssey scanner from LI-COR Biosciences (Lincoln, NE).

Protein Overexpression
----------------------

Strains carrying plasmids for exogenous overexpression of Cdc17, Mcm10, Pol12, Pri1, and Pri2 were grown overnight in minimal medium with 2% raffinose. Proteins were overexpressed from a galactose promoter in the presence of 2% galactose or repressed in the presence of 2% glucose. Total protein was extracted using the trichloroacetic acid extraction protocol. Cdc17-2HA, Mcm10-3HA, Pol12-3HA, Pri1-3HA, Pri2-3HA, and α-tubulin were detected by Western blot using anti-HA (16B12) for HA-tagged proteins and anti--α-tubulin (B512).

Heat Shock Survival Assay
-------------------------

This assay was performed as described previously ([@B57]). Briefly, cells were grown in YPD liquid medium to OD~600~ = 1.0. Before and after incubation at 52°C for 5 min, appropriate aliquots were spread on YPD plates and incubated at 30°C for 3 d. Colonies were counted and data presented as percentage of colonies formed after heat shock.

Microsatellite Instability Assay
--------------------------------

Assay was performed as described previously ([@B22]) except for the following. Seven individual colonies from each strain tested were grown in liquid SC-his-trp-leu minimal medium with 2% galactose to saturation. From each culture, 10^7^ cells were spread on SC-trp plates containing 1 mg/ml 5-FOA and 100 cells were spread on SC-trp plates for a viable cell count. Plates were incubated at 30°C for 4--5 d and FOA^R^ colonies were counted. The frequency of FOA^R^ clones was calculated by dividing the number of FOA^R^ colonies by the number of viable cells. To assess whether microsatellites were altered, pSH44 was recovered from FOA^R^ clones and the microsatellite region was sequenced. For clones in which the microsatellite was unaltered, pSH44 was digested with *Hin*dIII to detect gross sequence changes. Sequencing of these plasmids indicated that all of them had lost the microsatellite region, which was replaced with *LEU2* sequence that likely recombined with the upstream *LEU2* promoter sequence that immediately precedes the microsatellite tract in pSH44 ([@B23]). We constructed a control plasmid for this assay that had the same auxotrophic markers as pSH44 but lacked a microsatellite tract. To this end, *TRP1* was inserted into the multicloning site of pRS316 with *Kpn*I and *Sac*I.

Microscopy
----------

For nuclei staining, DAPI stain (10 μg/ml, Sigma, St. Louis, MO, D1380) was added to cultures for 30 min, washed twice with sterile water, air-dried on a microscope slide, and visualized using a Zeiss AxioplanII microscope with a DIC Alpha Plan-Fluar ×100/1.45 objective and DAPI filter. Ubc4-GFP and Ubc4-NES-GFP were visualized using a GFP filter. All images were captured using an Axiocam HRm camera and Axiovision software 4.0.

RNA Extraction and RT-PCR
-------------------------

Total RNA extraction was performed with the Qiagen RNeasy kit according to the manufacturer\'s protocol. Total RNA was digested with RNase-free DNase (Ambion, Austin, TX). Digested RNA (30, 6, and 3 ng) was subjected to a one-step RT-PCR reaction using the Superscript III One-Step RT-PCR kit (Invitrogen). The PCR cycle used was as follows: 52°C for 30 min followed by 94°C for 2 min and 30 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 30 s. *CDC17* was amplified with primer 5′ *CDC17*-3454 (5′-GCTCTAAGAATGCGTAAGGCTGGTAG-3′) and primer 3′ *CDC17*-3712 (5′-CAAACGCACCACGTTGAAGCTATC-3′) and *ACT1* was amplified with primer 5′ *ACT1*-511 (5′-GTTACCCAATTGAACACGGTATTGTC-3′) and primer 3′ *ACT1*-836 (5′-CAAAATGGCGTGAGGTAGAGAGAAAC-3′).

RESULTS
=======

Cdc17 Degradation Is Proteasome-Dependent
-----------------------------------------

Our laboratory has previously shown that Cdc17 is rapidly degraded when Mcm10 is depleted from yeast cells ([@B50], [@B51]). The fact that this pathway is conserved in human cells ([@B8]) implies that it serves an important function. Thus, we were interested in elucidating the mechanism of the Cdc17 degradation pathway. Because Cdc17 was degraded very rapidly, we hypothesized that its turnover might be mediated by the proteasome. To test this hypothesis, we inhibited the proteasome and monitored Cdc17 levels in the absence of Mcm10 using the temperature sensitive *mcm10-1* mutant ([@B36]; [@B54]). We deleted *RPN4* and *PDR5* to sensitize cells to treatment with the proteasome inhibitor MG132 ([@B53]; [@B17]). As expected, addition of MG132 at 30°C had no effect ([Figure 1](#F1){ref-type="fig"}). When cells were shifted to 37°C in the presence of DMSO, Cdc17 was degraded. In contrast, when cells were shifted to 37°C in the presence of MG132, Cdc17 was stabilized ([Figure 1](#F1){ref-type="fig"}), suggesting that Cdc17 degradation is proteasome-dependent.

![Cdc17 degradation is proteasome-dependent. ABy527 (*mcm10-1, pdr5*Δ, *rpn4*Δ) cells were grown in rich liquid medium at 25°C to midlog phase and split in four. MG132 was added to two of the cultures, DMSO was added to the other two, and cultures were shifted either to 30°C or 37°C for 180 min. Cdc17--3HA and α-tubulin were analyzed by Western blot.](zmk0181095680001){#F1}

Ubc4 Is Required for Cdc17 Degradation
--------------------------------------

We next wanted to identify the ubiquitin conjugating enzyme (E2) and the ubiquitin ligase (E3) responsible for Cdc17 degradation. There are only 11 E2 enzymes in yeast and only one, Cdc34, is essential ([@B25]). We therefore screened a collection of yeast strains that each lack a different nonessential E2 enzyme by overexpressing Cdc17. In addition, we overexpressed Cdc17 in strains lacking *MMS2* ([@B26]), an E2 enzyme variant, and *CUL3* and *RTT101*, both of which are components of separate E3 ligase complexes ([@B38]). Because overexpressed Cdc17 is unstable ([@B43]), we reasoned that it would rapidly disappear in all strains except the one lacking the E2 enzyme required for its degradation. We overexpressed Cdc17 under the control of a galactose-inducible promoter from a high copy plasmid as described previously ([@B51]). To monitor Cdc17 stability, we grew cells in liquid medium to midlog phase, induced Cdc17 expression by adding galactose, then added glucose to inhibit Cdc17 expression and observed Cdc17 protein levels by Western blot over the course of three hours. Cdc17 was indeed unstable when overexpressed in our strain background. The protein was nearly undetectable 3 h after glucose addition ([Figure 2](#F2){ref-type="fig"}). In most strains, overexpressed Cdc17 was degraded with kinetics very similar to those observed in wild-type cells with the notable exception of *ubc4*Δ mutants ([Figure 2](#F2){ref-type="fig"}). Cdc17 was significantly stabilized in *ubc4*Δ cells compared with all other strains, including *ubc5*Δ mutants ([Figure 2](#F2){ref-type="fig"}). We determined that Cdc17 overexpression levels in *ubc4*Δ mutants were ∼10-fold higher than in wild-type cells by diluting our protein extracts (data not shown). Although Ubc4 and Ubc5 are 93% identical and largely functionally redundant, we attribute this discrepancy to the differential regulation of Ubc4 and Ubc5. *UBC5* mRNA is of low abundance in log phase cells ([@B57]) and, although present at steady state levels similar to Ubc4, Ubc5 protein is much less stable ([@B48]). We concluded from this data that Ubc4 functions as the E2 enzyme in the ubiquitin-mediated degradation of overexpressed Cdc17 in cycling yeast cells.

![Overexpressed Cdc17 is stable in *ubc4*Δ cells. Strains were grown overnight in minimal medium with 2% raffinose. Cdc17-2HA was overexpressed from a galactose promoter in the presence of 2% galactose for 2 h. Cells were pelleted, resuspended in YPD, and samples were taken at 0, 60, 120, and 180 min after addition of glucose. Cdc17-2HA and α-tubulin, which served as a loading control, were analyzed by Western blot. The graphs show the quantification of Cdc17 relative to α-tubulin at each time point in each mutant strain relative to wild-type. The wild-type data in each graph are from the same experiment.](zmk0181095680002){#F2}

Because Ubc4 has been implicated in the degradation of misfolded proteins ([@B57]), it was possible that overexpressed Cdc17 is aberrantly folded and the requirement of Ubc4 for the degradation of overexpressed Cdc17 is not physiologically relevant. Therefore, we determined whether degradation of endogenous Cdc17 also required Ubc4. We deleted *UBC4* in *mcm10-1* mutants in which Cdc17 is tagged with three hemagglutinin (HA) epitopes and monitored Cdc17 stability in the absence of Mcm10. On Mcm10 depletion at 37°C, Cdc17 was degraded in the presence of Ubc4, as expected ([Figure 3](#F3){ref-type="fig"}, A and B; [@B50]). Conversely, when Mcm10 was depleted from *mcm10-1 ubc4*Δ cells, Cdc17 remained stable ([Figure 3](#F3){ref-type="fig"}, A and B). To ensure that Cdc17 stability was specific to *mcm10-1 ubc4*Δ cells, we monitored Cdc17 stability in *mcm10-1 ubc5*Δ, *mcm10-1 rad6*Δ, *mcm10-1 ubc13*Δ, and *mcm10-1 mms2*Δ double mutants. None of the other gene deletions had a significant effect ([Figure 3](#F3){ref-type="fig"}, A and B). We observed a slight but reproducible mobility shift in Cdc17--3HA when it was degraded. Whether this shift was due to protein modification is unclear. Notably, this shift was absent in *ubc4*Δ cells ([Figure 3](#F3){ref-type="fig"}A). We concluded that endogenous Cdc17 degradation following depletion of Mcm10 is Ubc4-dependent.

![Ubc4 is the E2 enzyme required for endogenous Cdc17 degradation in the absence of Mcm10. (A) Asynchronous cultures of ABy448 (W303-1a), ABy013 (*mcm10-1*), ABy342 (*mcm10-1*, *ubc4*Δ), ABy363 (*mcm10-1*, *ubc5*Δ), and ABy359 (*mcm10-1, rad6*Δ) grown at 25°C were shifted to 37°C for 180 min. Cdc17--3HA and α-tubulin were analyzed by Western blot. (B) The graph shows Cdc17/tubulin ratios at each time point for each strain relative to wild-type at time 0 (average of 3 separate experiments, bars represent mean ± SD).](zmk0181095680003){#F3}

Not4 Is the E3 Ligase Responsible for Cdc17 Destabilization
-----------------------------------------------------------

To identify the E3 ligase that cooperates with Ubc4 in Cdc17 destabilization, we took a candidate approach. Contrary to the small number of E2 enzymes in yeast, there are ∼100 E3 ligases in budding yeast ([@B31]). Although it would have been possible to screen 100 deletion strains, we took advantage of the fact that cells lacking Ubc4 along with Ubc5 have several characteristic phenotypes. For example, *ubc4*Δ *ubc5*Δ double mutants are resistant to heat shock and translational inhibitors ([@B57]; [@B10]). To identify candidate E3 ligases, we searched the literature for E3 ligase-deletion strains that phenocopied the heat shock resistance of *ubc4*Δ *ubc5*Δ cells. The E3 ligase Not4 fulfilled this criterion ([@B41]). Furthermore, Not4 binds Ubc4, has Ubc4-dependent ubiqutination activity in vitro, and associates with the proteasome ([@B47]; [@B32]; [@B41]). Thus, we deleted *NOT4* in *mcm10-1* mutants and tested whether this gene is involved in Cdc17 degradation. When we shifted *mcm10-1 not4*Δ cells to the nonpermissive temperature of 37°C to deplete Mcm10, Cdc17 remained stable in the absence of Mcm10, to the same extent as in *mcm10-1 ubc4*Δ double mutants ([Figure 4](#F4){ref-type="fig"}, A and B). To ensure that the observed Cdc17 stability was due to the E3 ligase activity of Not4 we constructed *not4-L35A*, which is unable to bind Ubc4 ([@B41]). We performed a temperature shift experiment as described above with *mcm10-1* mutants, *mcm10-1 not4*Δ double mutants, and *mcm10-1 not4*Δ double mutants supplemented with either pRS316-*NOT4* or pRS316-*not4-L35A*. Cdc17 degradation was largely rescued in cells in which *NOT4* was added back, but not in cells with *not4-L35A*, suggesting that Not4\'s E3 ligase activity was indeed required for the destabilization of Cdc17 ([Figure 4](#F4){ref-type="fig"}, C and D). The incomplete rescue of Cdc17 degradation was likely due to decreased expression of Not4 protein from the plasmid ([Figure 4](#F4){ref-type="fig"}E, compare middle lane to left lane).

![Not4 is the E3 ligase required for endogenous Cdc17 degradation in the absence of Mcm10. (A) Asynchronous cultures of ABy013 (*mcm10-1*), ABy342 (*mcm10-1*, *ubc4*Δ), and ABy529 (*mcm10-1, not4*Δ) grown at 25°C were shifted to 37°C for 180 min. Cdc17--3HA and α-tubulin were analyzed by Western blot. (B) The graph shows Cdc17/tubulin ratios at each time point for each strain relative to *mcm10-1* at time 0 (average of 3 separate experiments, bars represent mean ± SD). (C) Asynchronous cultures of ABy781 (*mcm10-1*, pRS316), ABy762 (*mcm10-1*, *not4*Δ, pRS316), ABy738 (*mcm10-1, not4*Δ, pRS316-*NOT4*), and ABy739 (*mcm10-1, not4*Δ, pRS316-*not4-L35A*) grown at 25°C were shifted to 37°C for 180 or 360 min. Cdc17--3HA and α-tubulin were analyzed by Western blot. (D) The graph shows Cdc17/tubulin ratios at each time point for each strain relative to ABy781 at time 0 (average of 3 separate experiments, bars represent mean ± SD). (E) Asynchronous cultures of ABy596 (*mcm10-1, NOT4-3HA*), ABy740 (*mcm10-1, not4*Δ, pRS316-*NOT4-3HA*), and ABy741 (*mcm10-1, not4*Δ, pRS316-*not4-L35A-3HA*) were grown in SC-ura liquid medium at 25°C to midlog phase. Not4-3HA and α-tubulin were analyzed by Western blot. (F) ABy661 (*mcm10-1, pdr5*Δ, *rpn4*Δ, YEp105) and ABy1051 (*mcm10-1, pdr5*Δ, *rpn4*Δ, YEp105-G75,76A) were grown in rich medium to OD~600~ = 0.6 at 25°C and shifted to 37°C for 3 h. Total protein was precipitated with trichloroacetic acid and analyzed by Western blot using anti-HA and anti-tubulin antibodies.](zmk0181095680004){#F4}

Because Cdc17 was stabilized in *mcm10-1* cells in the presence of MG132 ([Figure 1](#F1){ref-type="fig"}), we attempted to detect ubiquitinated Cdc17. Unfortunately, we were unable to detect ubiquitin-protein conjugates, although we performed immunoprecipitation experiments under both native and denaturing conditions (data not shown). To address whether ubiquitination was necessary for Cdc17 destabilization, we overexpressed synthetic wild-type or mutant ubiquitin in *mcm10-1 pdr5*Δ *rpn4*Δ cells. Clearly, expression of the G75,76A ubiquitin mutant ([@B13]), which is incompetent for isopeptide bond formation blocked Cdc17 degradation, whereas wild-type ubiquitin had no effect ([Figure 4](#F4){ref-type="fig"}F). Based on the results presented in [Figure 4](#F4){ref-type="fig"}, we argue that Ubc4 acts in concert with the E3 ligase Not4 to destabilize Cdc17 in the absence of Mcm10. However, it remains unclear whether Cdc17 is a direct target of ubiquitination.

Cdc17 Degradation Occurs in the Nucleus
---------------------------------------

Because Ubc4 and Not4 localize to the cytoplasm as well as the nucleus, we addressed where in the cell Cdc17 is degraded. Although Cdc17 is localized to the nucleus, it is possible that the protein is translocated to the cytoplasm before degradation. To determine whether Cdc17 is degraded in the nucleus or the cytoplasm we fused a strong nuclear export signal (NES) ([@B65]) along with 3 HA epitopes to the C terminus of Ubc4 to restrict its localization to the cytoplasm. We confirmed that Ubc4-NES-3HA retained its function by testing the allele in a heat shock assay ([@B57]). As mentioned above, *ubc4*Δ *ubc5*Δ cells are resistant to heat shock ([@B57]). If Ubc4-NES-3HA is not a functional enzyme, then *UBC4-NES-3HA ubc5*Δ double mutants should be resistant to heat shock. However, when we tested this particular strain, it was not resistant to heat shock, suggesting that Ubc4-NES-3HA retained E2 enzyme function ([Figure 5](#F5){ref-type="fig"}A). We also confirmed that Ubc4-NES-3HA was primarily cytoplasmic by fusing GFP to its C-terminus and observing its cellular localization by fluorescence microscopy ([Figure 5](#F5){ref-type="fig"}B). Having verified that Ubc4-NES-3HA is a functional cytoplasmic enzyme, we then determined whether Cdc17 was degraded in the nucleus or the cytoplasm. If Cdc17 degradation occurred in the nucleus, then Cdc17 should have remained stable in *mcm10-1 UBC4-NES-3HA* double mutants. Conversely, if Cdc17 was degraded in the cytoplasm, then Cdc17 should have been degraded after Mcm10 depletion from *mcm10-1 UBC4-NES-3HA* cells. Our experiments showed that the former was the case, although Cdc17 was not as stable in *UBC4-NES-3HA* cells as in *ubc4*Δ mutants ([Figure 5](#F5){ref-type="fig"}, C and D). We attribute this difference in stability to the fact that a small portion of *mcm10-1 UBC4-NES-3HA* cells may not have efficiently excluded Ubc4 from the nucleus. Thus, the cells with Ubc4 in the nucleus were able to degrade Cdc17 and this resulted in overall lower levels of Cdc17 in the entire population of cells compared with *ubc4*Δ mutants. These data strongly suggested that Cdc17 is degraded primarily in the nucleus in an Ubc4- and Not4-dependent manner.

![Cdc17 is degraded primarily in the nucleus. (A) ABy150 (S288C), ABy152 (*ubc4*Δ), ABy574 (*UBC4-NES-3HA*), ABy577 (*ubc5*Δ, *UBC4-NES-3HA*), and GAP510 (*ubc4*Δ, *ubc5*Δ) were heat shocked as described in the *Materials and Methods*, aliquots were grown on YPD plates for 3 d at 30°C, and colonies were counted to determine the percentage of cells that were viable following heat shock. (B) ABy605 (*mcm10-1, UBC4-GFP*) and ABy660 (*mcm10-1, UBC4-NES-GFP*) were examined using fluorescence microscopy. Merge represents GFP and DAPI. Yellow dots represent colocalization of Ubc4-GFP and DAPI-stained nuclei. Red dots represent DAPI-stained nuclei in which Ubc4-GFP is not present. Black circles represent vacuoles. (C) Asynchronous cultures of ABy013 (*mcm10-1*), ABy342 (*mcm10-1*, *ubc4*Δ), ABy455 (*mcm10-1, UBC4-NES-3HA*), ABy363 (*mcm10-1*, *ubc5*Δ), and ABy359 (*mcm10-1, rad6*Δ) grown at 25°C were shifted to 37°C for 180 min. Cdc17--3HA and α-tubulin were analyzed by Western blot. (D) The graph shows Cdc17/tubulin ratios at each time point for each strain relative to *mcm10-1* at time 0 (average of 3 separate experiments, bars represent mean ± SD).](zmk0181095680005){#F5}

In the light of the fact that Not4 has been strongly implicated in transcriptional regulation and has thus far not been linked to the turnover of replication factors, we wondered whether Cdc17 transcript levels were affected in the various mutants that we analyzed in this study. To this end, we isolated total RNA and performed semiquantitative RT-PCR. We did not observe any significant changes in Cdc17 transcript levels ([Figure 6](#F6){ref-type="fig"}), arguing that Ubc4/Not4 do not affect Cdc17 transcription.

![*CDC17* mRNA levels are unchanged in *not4*Δ mutants. ABy448 (W303-1a), ABy013 (*mcm10-1*), ABy342 (*mcm10-1, ubc4*Δ), ABy455 (*mcm10-1, UBC4-NES*), ABy529 (*mcm10-1, not4*Δ), ABy363 (*mcm10-1, ubc5*Δ), ABy359 (*mcm10-1, rad6*Δ), ABy360 (*mcm10-1, ubc13*Δ), and ABy361 (*mcm10-1, mms2*Δ) were grown in rich medium to midlog phase at 25°C and shifted to 37°C for 180 min. Total RNA was extracted from cells taken just before the shift to 37°C and after 180 min at 37°C. Semiquantitative RT-PCR was performed on each sample using 30, 6, and 3 ng total RNA with primers specific for either *CDC17* or *ACT1*.](zmk0181095680006){#F6}

Cdc17 Levels Are Elevated in the Presence of Mcm10 in ubc4Δ and not4Δ Cells
---------------------------------------------------------------------------

Cdc17 is transcribed and translated at the G1/S transition of every cell cycle ([@B63]), yet steady-state levels of Cdc17 remain unchanged throughout the cell cycle ([@B43]). It is possible that Cdc17 levels remain stable via degradation of any excess Cdc17 by Ubc4 and Not4. Because Mcm10 stabilizes Cdc17 ([@B50], [@B51]; [@B8]), we asked whether steady-state levels of the catalytic subunit of pol-α were elevated in the presence of Mcm10-1 when Cdc17 degradation was disrupted. We grew asynchronous cultures of *ubc4*Δ, *UBC4-NES*, *not4*Δ, *ubc5*Δ, *rad6*Δ, *ubc13*Δ, and *mms2*Δ cells (all in the *mcm10-1* background) to midlog phase and analyzed the steady-state levels of Cdc17 by Western blot. The protein accumulated approximately twofold in *ubc4*Δ, *UBC4-NES*, and *not4*Δ cells ([Figure 7](#F7){ref-type="fig"}, A and B), whereas no significant increase was observed in *ubc5*Δ, *rad6*Δ, *ubc13*Δ, or *mms2*Δ cells. We observed similar trends in *ubc4*Δ, *not4*Δ and *ubc5*Δ mutants that carried the wild-type gene for *MCM10*, although the effect was most pronounced in *not4*Δ cells ([Figure 7](#F7){ref-type="fig"}C). We concluded from these data that cells keep Cdc17 levels tightly regulated not only through Ubc4- and Not4-mediated degradation, but also by limiting the amount of Mcm10 that is available to bind and stabilize Cdc17.

![Cdc17 levels are elevated twofold in the presence of Mcm10 in *ubc4*Δ, *UBC4-NES-3HA*, and *not4*Δ cells. (A) Asynchronous cultures of ABy013 (*mcm10-1*), ABy342 (*mcm10-1*, *ubc4*Δ), ABy455 (*mcm10-1, UBC4-NES-3HA*), ABy363 (*mcm10-1*, *ubc5*Δ), ABy359 (*mcm10-1, rad6*Δ), ABy360 (*mcm10-1, ubc13*Δ), ABy361 (*mcm10-1, mms2*Δ), and ABy529 (*mcm10-1, not4*Δ) were grown at 25°C to midlog phase. Cdc17--3HA and α-tubulin were analyzed by Western blot. (B) The graph shows the fold change in Cdc17 in each strain relative to *mcm10-1* (average of 3 separate experiments, bars represent mean ± SD). (C) Asynchronous cultures of ABy448 (W303-1a), ABy607 (*ubc4*Δ), ABy597 (*not4*Δ), and ABy764 (*ubc5*Δ) were grown at 25°C to midlog phase. Cdc17--3HA and α-tubulin were analyzed by Western blot. The values represent the fold change in Cdc17 levels relative to wild-type.](zmk0181095680007){#F7}

Nuclear Ubc4 Is Important for Replication Stress Tolerance
----------------------------------------------------------

Because cells keep Cdc17 tightly regulated, we hypothesized that elevation of Cdc17 steady-state levels may have functional consequences during DNA replication. It has been shown previously that *not4*Δ cells are extremely sensitive to hydroxyurea (HU), which correlates with Not4\'s role in the transcriptional upregulation of ribonucleotide reductase ([@B42]). Cells lacking Ubc4 have been shown to be moderately sensitive to HU, but the reason for this sensitivity was not explained ([@B41]), and we were curious as to whether it pertains to the nuclear function of Ubc4. Thus, we subjected *UBC4-NES-3HA* cells to HU treatment to determine whether Ubc4\'s nuclear localization is important for replication stress tolerance. Interestingly, *UBC4-NES-3HA* cells behaved identically to *ubc4*Δ cells ([Figure 8](#F8){ref-type="fig"}A). Whereas *ubc4*Δ mutants were moderately sensitive to HU, *not4*Δ cells were highly sensitive to the drug, as seen previously ([Figure 8](#F8){ref-type="fig"}A). Cells lacking Ubc5 were no more sensitive to HU than wild-type cells. These results suggested that Ubc4 has a function in the nucleus that is important for replication stress tolerance.

![Ubc4 is required in the nucleus for tolerance to hydroxyurea. (A) Successive 10-fold dilutions of ABy448 (W303-1a), ABy607 (*ubc4*Δ), ABy662 (*UBC4-NES-3HA*), ABy597 (*not4*Δ), ABy764 (*ubc5*Δ), ABy013 (*mcm10-1*), ABy342 (*mcm10-1, ubc4*Δ), ABy455 (*mcm10-1, UBC4-NES-3HA*), ABy529 (*mcm10-1, not4*Δ), and ABy363 (*mcm10-1, ubc5*Δ) were grown for 3 d at 30°C on YPD plates and YPD containing 50 mM, 100 mM, and 200 mM HU. (B) Asynchronous cultures of ABy597 (*not4*Δ) and ABy529 (*mcm10-1, not4*Δ) were grown to midlog phase. Cdc17--3HA and α-tubulin were analyzed by Western blot in undiluted extracts and extracts diluted 10-fold, 25-fold, and 50-fold.](zmk0181095680008){#F8}

To address whether Cdc17 plays a role in the observed HU sensitivity, we repeated the experiment in *mcm10-1* mutants. Because the *mcm10-1* mutation affects Cdc17 stability at 30°C ([@B51]), we predicted that the HU sensitivity should be alleviated in the double mutants, despite the fact that the *mcm10-1* strain displays a higher HU sensitivity than wild-type cells ([Figure 8](#F8){ref-type="fig"}A). This was indeed the case. Surprisingly, even the severe HU sensitivity of *not4*Δ mutants was suppressed by *mcm10-1* ([Figure 8](#F8){ref-type="fig"}A). This suppression went hand-in-hand with reduced Cdc17 levels in *mcm10-1 not4*Δ double mutants ([Figure 8](#F8){ref-type="fig"}B; we estimate a 2.5- to fivefold reduction compared with *not4*Δ). Therefore, the level of Cdc17 expression correlates well with the degree of HU sensitivity in *not4*Δ cells although we cannot exclude the possibility that *mcm10-1* ameliorates effects of replication stress in *not4*Δ mutants in a Cdc17-independent manner.

Overexpression of Cdc17 and Mcm10 Causes Slow Growth
----------------------------------------------------

We hypothesized that there may be other defects caused by elevated Cdc17 levels that occurred at low frequency, such that they would not be readily detected. To test this hypothesis we overexpressed Cdc17, along with its binding partner Mcm10, to exacerbate the effect of disrupting Cdc17 degradation. We overexpressed Cdc17 and Mcm10 from plasmids under the control of a galactose promoter ([Figure 9](#F9){ref-type="fig"}A). To our surprise, 10-fold overexpression of Cdc17 and Mcm10 resulted in a significant growth defect in the absence of any exogenous stress ([Figure 9](#F9){ref-type="fig"}B). According to our estimate, growth was inhibited ∼25-fold. Importantly, cells carrying the empty vector controls did not display any growth phenotype ([Figure 9](#F9){ref-type="fig"}B). Overexpression of Cdc17 alone did not affect growth, likely because Mcm10 was not present at high enough levels to recruit excess Cdc17 to chromatin where it functions during DNA replication ([@B51]). Similarly, overexpression of Mcm10 alone had little effect, suggesting that the primary reason for the proliferation inhibition was the excess of Cdc17. It was possible that the growth defect we observed upon cooverexpression of Cdc17 and Mcm10 was due to sequestration of the rest of the pol-α/primase complex. To address this possibility, we overexpressed the remaining subunits of pol-α/primase, Pol12, Pri1, and Pri2, together with Mcm10 and Cdc17 ([Figure 9](#F9){ref-type="fig"}A). However, this did not rescue the observed phenotype ([Figure 9](#F9){ref-type="fig"}B). From these data we concluded that careful regulation of Cdc17 is required for cells to undergo normal proliferation.

![Overexpression of Cdc17 and Mcm10 causes slow growth. (A) Strains containing the indicated plasmids were grown in media containing 2% raffinose to midlog phase, either 2% galactose (GAL) or 2% glucose (GLU) was added, and cells were grown for an additional 2 h. Cdc17-2HA, Mcm10-3HA, Pol12--3HA, Pri1--3HA, and Pri2--3HA were analyzed by Western blot. (B) Successive 10-fold dilutions of ABy695 (empty vectors), ABy694 (*GAL-CDC17-2HA*), ABy696 (*GAL-MCM10-3HA*), ABy705 (*GAL-CDC17-2HA*, *GAL-MCM10-3HA*), and ABy732 (*GAL-CDC17-2HA, GAL-MCM10-3HA, GAL-POL12--3HA, GAL-PRI1--3HA, GAL-PRI2--3HA*) were grown for 3 d at 30°C on SC-his-trp-ura with 2% glucose plates and SC-his-trp-ura with 2% galactose plates.](zmk0181095680009){#F9}

Overexpression of Cdc17 and Mcm10 Induces Genome Instability
------------------------------------------------------------

As mentioned earlier, Cdc17 lacks proofreading activity, making it a potentially mutagenic enzyme ([@B40]). We therefore reasoned that higher levels of Cdc17 and Mcm10 might cause an elevated mutation rate in cells. To test this idea, we overexpressed either Cdc17 alone, Mcm10 alone, or Cdc17 with Mcm10 in wild-type cells and monitored the ability of these cells to acquire resistance to canavanine, a toxic amino acid analog ([@B66]). Individual colonies of each strain were grown in liquid medium containing galactose (to induce protein overexpression) to saturation and then plated on solid medium containing canavanine. A dilution of each culture was also plated on rich solid medium for a viable cell count. The numbers of canavinine-resistant (Can^R^) colonies were counted after 3--4 d growth at 30°C. Cells overexpressing both Cdc17 and Mcm10 showed a fivefold increase in mutation rate, whereas cells overexpressing Cdc17 or Mcm10 alone showed no significant increase in mutation rate ([Figure 10](#F10){ref-type="fig"}A). Cells containing overexpression vectors for Cdc17 and Mcm10 grown in glucose served as a negative control. We also tested *ubc4*Δ and *not4*Δ mutants and they displayed a 1.6- and 2.5-fold increase in Can^R^ colonies ([Figure 10](#F10){ref-type="fig"}A).

![Overexpression of Cdc17 and Mcm10 increases genome instability. (A) Seven individual colonies of ABy563 (pRS426gal-*CDC17-2HA*), ABy564 (pRS423gal-*MCM10-3HA*), and ABy565 (pRS423gal-*MCM10-3HA*, pRS426gal-*CDC17-2HA*) were grown to saturation in the presence of 2% galactose, and seven colonies of ABy565 were grown to saturation in the presence of 2% glucose. Cells were grown on -arg plates containing canavanine (60 mg/L) to select for mutants and on YPD plates for a viable cell count. Colonies were counted after 2--3 d at 30°C. (B) Strains containing the indicated plasmids were grown in media containing 2% raffinose to midlog phase, either 2% galactose (GAL) or 2% glucose (GLU) was added, and cells were grown for an additional 2 h. Cdc17-2HA and Mcm10-3HA were analyzed by Western blot. (C) Seven individual colonies each from ABy640, ABy641, ABy642, and ABy643 were grown in SC-his-trp-leu with 2% galactose to saturation at 30°C. From each culture, 100 cells were plated on SC-trp with 2% glucose medium and 10^7^ cells were plated on SC-trp with 2% glucose and 1 mg/ml 5-FOA medium. Plates were incubated for 5 d at 30°C and colonies were counted. (D) pSH44 was isolated from 5-FOA-resistant clones and digested with *Hin*dIII, which produces a 4.3-kb fragment (backbone) and a 3.6-kb fragment \[poly(GT)-*URA3* coding sequence\] in the wild type plasmid. Digested plasmids showed either no detectable size change (circles) or complex rearrangements (squares). (E) Same as in C, but with the addition of strains ABy977, ABy978, ABy979 and ABy980, which contain pRS316-*TRP1* in place of pSH44.](zmk0181095680010){#F10}

Different pol-α mutants have also been shown to induce microsatellite instability in budding yeast ([@B22]). We hypothesized that elevated levels of Cdc17 and Mcm10 might have the same effect because they interfere with normal proliferation ([Figure 9](#F9){ref-type="fig"}B). To test this hypothesis, we used a plasmid-based assay to measure microsatellite instability ([@B23]; [@B22]). In this assay, a plasmid (pSH44) containing an in-frame insertion of a poly (GT) tract upstream of *URA3* was transformed into cells that contained either empty vector, vectors with galactose-inducible *CDC17* or *MCM10* alone, or vectors with galactose-inducible *CDC17* and *MCM10*, rendering these cells Ura^+^ ([@B23]). Alterations in the poly (GT) tract that change the reading frame result in Ura^−^ cells, and these cells can be selected for on 5-fluoroorotic acid (5-FOA)-containing medium ([@B5]). We found that cells overexpressing both Cdc17 and Mcm10 disrupted the *URA3* gene at an ∼20-fold higher rate than cells that carried empty vector controls ([Figure 9](#F9){ref-type="fig"}, B and C). Conversely, cells overexpressing Cdc17 alone showed no increase in mutation rate, whereas cells overexpressing Mcm10 alone showed a fourfold increase in mutation rate ([Figure 9](#F9){ref-type="fig"}, B and C). To verify that 5-FOA resistant (FOA^R^) cells carried mutations in the microsatellite tract we attempted to recover the plasmids of 30 colonies. Only 13 of these gave rise to ampicillin resistant bacteria colonies. DNA sequencing revealed that 5/13 had an intact poly (GT) tract, whereas 8/13, or ∼60%, had lost the microsatellite tract, indicating that the plasmid DNA was rearranged. To confirm this finding, we cleaved the plasmids with HindIII, which should yield a 3.6- and 4.3-kb fragment ([@B22]). All plasmids that had lost the poly (GT) tract displayed DNA rearrangements ([Figure 10](#F10){ref-type="fig"}D). To further ascertain that the rearrangements were dependent on the microsatellite tract, we compared the number of FOA^R^ colonies between pSH44 and pRS316-*TRP1*, which is devoid of a poly (GT) tract. Whereas the former exhibited a 20-fold change, we only observed a fivefold increase in mutation rate for the latter in cells that cooverexpressed Cdc17 and Mcm10 ([Figure 10](#F10){ref-type="fig"}E). Therefore, the majority of plasmid rearrangements must have been triggered by replication through the microsatellite tract. Together, these findings demonstrate that disregulation of Cdc17 and Mcm10 can induce microsatellite-mediated DNA recombination.

Overexpression of Cdc17 Results in Synthetic Dosage Lethality with not4Δ
------------------------------------------------------------------------

Thus far, all of our functional assays used the cooverexpression of Cdc17 and Mcm10. However, if cells are defective for Cdc17 degradation, the protein should accumulate and ultimately interfere with cell viability or fitness independently of cooverexpression of Mcm10. To test this prediction, we overexpressed either Cdc17 or Mcm10 in *ubc4*Δ, *ubc5*Δ, *ubc4*Δ *ubc5*Δ, and *not4*Δ mutants. Because *ubc4*Δ *ubc5*Δ double and *not4*Δ single mutants grow more slowly than the other strains, we evaluated cell growth after 3 and 5 d, respectively. [Figure 11](#F11){ref-type="fig"}A shows that Cdc17 and Mcm10 were induced at similar levels in all strains after 1 h in galactose-containing medium. As predicted, *ubc4*Δ mutants exhibited a significant growth defect when Cdc17, but not Mcm10, was overexpressed ([Figure 11](#F11){ref-type="fig"}B). The effect was even more pronounced in *ubc4*Δ *ubc5*Δ double and *not4*Δ single mutants, which displayed SDL with *CDC17* overexpression. In the case of *ubc4*Δ *ubc5*Δ double mutants, this was also true for *MCM10* ([Figure 11](#F11){ref-type="fig"}B). When we examined Cdc17 expression levels after overnight culture in galactose-containing medium, *ubc4*Δ and *not4*Δ cells had accumulated much higher levels of Cdc17 than the wild-type strain ([Figure 11](#F11){ref-type="fig"}C). The amount of Cdc17 protein detected in the different strains correlated well with the observed growth defect. These results are consistent with our claim that Ubc4 and Not4 regulate the degradation of Cdc17 either directly or indirectly.

![Overexpression of Cdc17 in *ubc4*Δ*ubc5*Δ and *not4*Δ mutants causes synthetic dosage lethality. (A) ABy962 (pRS423gal), ABy963 (*GAL-CDC17-2HA*), ABy964 (*GAL-MCM10-3HA*), ABy965 (*ubc4*Δ, pRS423gal), ABy966 (*ubc4*Δ, *GAL-CDC17-2HA*), ABy967 (*ubc4*Δ, *GAL-MCM10-3HA*), ABy968 (*ubc5*Δ, pRS423gal), ABy969 (*ubc5*Δ, *GAL-CDC17-2HA*), ABy970 (*ubc5*Δ, *GAL-MCM10-3HA*), ABy971 (*ubc4*Δ*ubc5*Δ, pRS423gal), ABy972 (*ubc4*Δ*ubc5*Δ, *GAL-CDC17-2HA*), ABy973 (*ubc4*Δ*ubc5*Δ, *GAL-MCM10-3HA*), ABy974 (*not4*Δ, pRS423gal), ABy975 (*not4*Δ, *GAL-CDC17-2HA*), and ABy976 (*not4*Δ, *GAL-MCM10-3HA*) were grown in media containing 2% raffinose to midlog phase, either 2% galactose (GAL) or 2% glucose (GLU) was added, and cells were grown for an additional hr. Cdc17-2HA, Mcm10-3HA, and α-tubulin were analyzed by Western blot. The asterisk indicates a nonspecific band recognized by the HA antibody. (B) Successive 10-fold dilutions of the strains in A were grown for the indicated time at 30°C on SC-his-trp-ura with 2% glucose plates and SC-his-trp-ura with 2% galactose plates. (C) ABy981 (*CDC17-3HA*, pRS426gal-*CDC17-2HA*), ABy831 (*ubc4*Δ, *CDC17--3HA*, pRS426gal-*CDC17-2HA*), and ABy837 (*not4*Δ, *CDC17--3HA*, pRS426gal-*CDC17-2HA*) were grown overnight in SC-ura medium to midlog phase. Cdc17 and α-tubulin were analyzed by Western blot.](zmk0181095680011){#F11}

DISCUSSION
==========

In this study, we demonstrate that Cdc17 turnover is dependent on Ubc4 and Not4. This was unexpected because Not4 was originally isolated as a transcriptional regulator ([@B11]). Not4 has also been shown to possess E3 ubiquitin ligase activity in vitro ([@B47]; [@B41]). It is part of the nine-subunit Ccr4-Not complex that regulates trimethylation of histone H3 lysine 4 ([@B9]; [@B32]). Importantly, we show that Cdc17 is not modulated at the transcript level ([Figure 6](#F6){ref-type="fig"}) but rather through ubiquitin-mediated proteasomal degradation ([Figures 1](#F1){ref-type="fig"} and [4](#F4){ref-type="fig"}). This degradation is likely triggered when Mcm10 is ubiquitinated and no longer interacts with pol-α ([@B12]) or the replisome becomes unstable ([@B33]). Our results suggest that yeast cells stabilize only enough Cdc17 to efficiently initiate replication. We propose that increased Cdc17 protein levels above a defined molecular threshold are detrimental to the cell and are therefore rapidly eliminated.

We have identified Cdc17 as a novel target of Not4-mediated degradation. Recently, Jhd2 (JmjC domain-containing histone demethylase) was reported to be a direct target of Not4 ([@B37]). In addition, Not4 may have a role in the degradation of Egd2, which is part of the ribosome-associated EGD (enhancer of Gal4 DNA binding) complex ([@B47]). However, none of these proteins has a role in DNA replication. Cdc17 is stable in the absence of Mcm10 in *not4*Δ cells ([Figure 4](#F4){ref-type="fig"}A) and accumulates in the presence of Mcm10 when *NOT4* is deleted ([Figure 7](#F7){ref-type="fig"}C). We take this as evidence that Not4 is required for regular turnover of Cdc17. This is supported by the observation that Cdc17 destabilization is clearly dependent on ubiquitin conjugation ([Figure 4](#F4){ref-type="fig"}F), although it remains elusive whether Cdc17 is a direct target of ubiquitination. In this context, it is worthwhile to note that precedence exists for ubiquitin-independent proteasomal degradation ([@B55]). In addition, we excluded that accumulation of Cdc17 in *mcm10-1 not4*Δ cells ([Figure 4](#F4){ref-type="fig"}A) was due to a failure to degrade Mcm10-1 protein at the nonpermissive temperature (data not shown). Another striking observation supporting the claim that Not4 regulates Cdc17 turnover in conjunction with Ubc4 is provided by the SDL tests ([Figure 11](#F11){ref-type="fig"}). SDL screens have been used to identify potential targets for protein kinases ([@B35]; [@B69]) and might also be useful in revealing potential targets for E3 ligases. One question such a screen could address is whether Cdc17 is the only replication factor regulated by Not4 or if Not4 controls the turnover of other replication proteins as well. Mcm10 does not appear to be a potential target as its overexpression had little effect on the viability of *not4*Δ cells ([Figure 11](#F11){ref-type="fig"}B). Nevertheless, a mutation in *MCM10* almost completely alleviated the severe HU-sensitivity of *not4*Δ cells ([Figure 8](#F8){ref-type="fig"}). Because *mcm10-1* is HU-sensitive by itself, one might have expected that it exacerbates the drug sensitivity of the *not4*Δ strain. We believe that these results are most easily explained by the destabilizing effect that *mcm10-1* has on Cdc17 ([@B51]; [@B33]).

The data presented here raise the possibility that ubiquitin-mediated degradation of Cdc17 occurs at or in close proximity of the replication fork. There have been other hints that the ubiquitination machinery operates at the replication fork, but direct evidence is lacking to date. For example, Dia2, an F-box protein, has been shown to bind origins of replication and promote genome stability, but no degradation target of Dia2 has been identified ([@B3]; [@B29]; [@B39]).

We propose that Ubc4 and Not4 may have a role in degrading Cdc17 to ensure efficient polymerase switching (pol-ε on the leading strand \[[@B49]\] and pol-δ on the lagging strand \[[@B46]\]). In support of this model, we demonstrated earlier that ubiquitinated Mcm10 binds PCNA, the processivity factor for pol-δ and pol-ε, but not pol-α ([@B12]). Therefore, it is possible that after pol-α synthesizes a short DNA primer, Mcm10 becomes ubiquitinated and interacts with PCNA, causing Cdc17 to be released from Mcm10. Once released, Cdc17 might then be targeted for proteasomal degradation ([Figure 12](#F12){ref-type="fig"}). We stress that a direct interaction between Cdc17 and Not4/Ubc4 is strictly hypothetical at present. Regardless of whether the interaction with Cdc17 is direct or indirect, Not4/Ubc4 could ensure that Cdc17, a potentially mutagenic enzyme, is not loaded back onto the DNA to further extend the RNA/DNA primer. The fivefold elevated mutation rate of cells overexpressing Cdc17 and Mcm10 ([Figure 10](#F10){ref-type="fig"}A) is consistent with a mechanism by which Mcm10 "redelivers" pol-α to chromatin, thus interfering with the switch from pol-α to pol-δ ([Figure 12](#F12){ref-type="fig"}). As a consequence, pol-α would further extend the RNA/DNA primer, which could account for the increased frequency of mutations ([Figure 10](#F10){ref-type="fig"}A). Tight regulation of Mcm10 by ubiquitination is likely a prerequisite for regular turnover of Cdc17. Therefore, Mcm10 has a dual role, not only stabilizing but also providing timely degradation to inhibit the accumulation of Cdc17.

![Overexpression of Mcm10 and Cdc17 may hinder polymerase switching. After pol-α extends the RNA primer (red line) by 12--20 nucleotides, Mcm10 is ubiquitinated at two distinct lysines (yellow star; ([@B12]). PCNA is recruited to the lagging strand, and a polymerase switch occurs between pol-α and pol-δ, after which pol-α is released from ubiquitinated Mcm10 and recognized by Ubc4 and Not4. The question mark denotes the fact that it is currently unclear whether the interaction is direct or indirect. Accumulation of Cdc17 and Mcm10 interferes with the switch to pol-δ, allowing pol-α to synthesize more DNA than in wild-type cells.](zmk0181095680012){#F12}

Inhibition of replicative pol activity induces chromosomal breaks, even at drug doses that are low enough to not affect the proliferation rate of cells ([@B20]). In addition, a mutant of Cdc17, *pol1--1*, increases mutation frequency and microsatellite instability in budding yeast ([@B22]). Furthermore, low levels of pol-α cause chromosomal translocations in budding yeast, even in the presence of a functional S phase checkpoint ([@B34]). All of these investigations demonstrate the effects of a decline in pol-α function. In contrast, we have shown here that increasing steady-state levels of wild-type pol-α causes genomic instability as well. In a plasmid-based in vivo assay, cooverexpression of Cdc17 and Mcm10 resulted in a significant increase in microsatellite-mediated recombination ([Figure 10](#F10){ref-type="fig"}, C--E). These events almost certainly require DNA breakage, and we speculate that breaks occur via improper progression of lagging strand synthesis. In this context it is interesting to note that a recent study in *Arabidopsis* suggests that the failure to properly switch from pol-α to pol-δ might trigger recombination events at replication forks ([@B56]).

DNA rearrangements have been linked to many different types of cancer ([@B18]; [@B44]). We hypothesize that microsatellite-induced instability could arise through increased levels of pol-α and its binding partner, Mcm10. In support of this hypothesis, p180, the catalytic subunit of pol-α in humans, and Mcm10 are up-regulated in glioma cells ([@B58]). Intriguingly, UbcH5, the human holomog of yeast Ubc4/5, is down-regulated in these cells. Furthermore, p180 and Mcm10 levels are increased, whereas CNOT4 levels, the human homolog of yeast Not4, are decreased in human male germ cell tumors ([@B30]). These data indicate that the degradation pathway identified here may also be important in human cells. More specifically, because the levels of p180, Mcm10, UbcH5, and CNOT4 are misregulated in cancer cells, this pathway may be important for cancer prevention and perhaps serve as a novel target for cancer therapy.
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Mcm

:   Minichromosome maintenance

pol-α

:   DNA polymerase-α

PCNA

:   proliferating cell nuclear antigen

Ubc

:   ubiquitin conjugating enzyme.
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